Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-06

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research hypothesis:

Switching from dual regimens based on dolutegravir plus a RTI to a single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), lowers the exposure to Residual Viremia (and hence the risk of viral rebound), without increasing treatment toxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551

HIV-1 HIV Infections Acquired Immunodeficiency Syndrome

COMPLETED PHASE3

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935

HIV-1 Infection

COMPLETED PHASE3

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596

HIV HIV Infections

COMPLETED PHASE3

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940

HIV HIV Infections Acquired Immunodeficiency Syndrome

COMPLETED PHASE3

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029

HIV-1 Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design Randomized, single-center, open-label, 96-week superiority study. Patients with HIV-RNA \<50 copies/mL while receiving DTG plus one RTI will be randomized 1:1 to continue the ongoing treatment or to switch to E/C/F/TAF.

Randomization list will be a computer-generated list (with equal block sizes) and will be incorporated within an electronic clinical report form (eCRF).

Patients will be evaluated at screening, baseline, week 4, 8, 16, 24, 32, 40, 48, 60, 72, 84, 96 or premature discontinuation.

At each visit the following evaluations will be performed:

1. clinical assessment.
2. routine laboratory tests (hematological tests and clinical chemistry). Additional blood samples will be collected at specified visits for storage and further determinations (e.g. RV by a single-copy assay).

During follow-up, at different timepoints, patients will additionally undergo HIV-DNA quantification in PBMCs (BL, 48 and 96 weeks) and quality of life (QOL) and adherence assessement (BL, 48 and 96 weeks).

Viral load will be assessed by Abbott Real time PCR (Abbott RealTime HIV-1) Residual viremia (RV) will be defined as any detectable HIV-RNA value below 50 copies/mL Virologic failure will be defined as a confirmed rebound in plasma HIV-RNA levels ≥ 50 copies/mL

Subjects who meet a protocol-defined virologic failure during follow-up will be discontinued from the study.

At virologic failure subjects will perform genotypic HIV resistance testing and a determination in plasma of elvitegravir or DTG Cthrough.

HIV-DNA will be extracted from 1x106 peripheral blood mononuclear cells (PBMCs) by using Qiagen DNA extraction kit and quantified by Real Time PCR (ABI Prism 7900).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Treatments

1. Genvoya 150Mg-150Mg-200Mg-10Mg Tablet ( 1 pill every 24 hours)
2. Dolutegravir 50 mg (1 pill every 24 hours) plus one Reverse Trascriptase Inhibitor (at label dose)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genvoya 150Mg-150Mg-200Mg-10Mg Table

switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)

Group Type EXPERIMENTAL

Genvoya 150Mg-150Mg-200Mg-10Mg Tablet

Intervention Type DRUG

switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.

Dolutegravir 50 mg plus one RTI (at label dose)

Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Group Type ACTIVE_COMPARATOR

Dolutegravir 50 mg plus one RTI

Intervention Type DRUG

Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genvoya 150Mg-150Mg-200Mg-10Mg Tablet

switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.

Intervention Type DRUG

Dolutegravir 50 mg plus one RTI

Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>18 years
2. Willing and able to provide informed consent
3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI
4. HIV-RNA \<50 copies/mL since at least 6 months

Exclusion Criteria

1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic chemotherapy)
2. Serious illness requiring systemic treatment and/or hospitalization
3. Current use of immunomodulant or immunosuppressive drugs
4. Need (or will likely need) of treatment with antacids
5. Use of drugs contraindicated with study drugs, according to technical sheets
6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous resistance tests (patients with the 184I/V mutation alone are allowed to enter the study)
7. Resistance or previous virological failure to InSTIs
8. Detectable HCV-RNA
9. Documented allergy to COBI or EVG or FTC or tenofovir.
10. Absolute neutrophil count (ANC) \<500/µL
11. Haemoglobin \<8.0 g/dL
12. Platelet count \<50,000/µL
13. eGFR \<30 mL/min/1.73m2 by CKD-EPI equation
14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)
15. Presence of Child Pugh Class B or C liver cirrhosis.
16. Pregnancy or breastfeeding
17. Woman of childbearing potential who does not agree to adopt highly effective contraception.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No